Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.47 |
| ▸ | CSF1R | P07333 | 3/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 7/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
| ▸ | GRK5 | P34947 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.42 |
| ▸ | SIK1 | P57059 | 1/20 | 0.42 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435901 | 0.91 | PTPN11 (0.46) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL30365147 | 0.91 | PTPN11 (0.46) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL31435919 | 0.89 | PTPN11 (0.43) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL31436004 | 0.89 | PTPN11 (0.49) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL31435954 | 0.88 | PTPN11 (0.43) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL31435998 | 0.88 | PTPN11 (0.46) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL31436014 | 0.88 | PTPN11 (0.43) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL31435953 | 0.88 | PTPN11 (0.43) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL31435955 | 0.87 | PTPN11 (0.42) | NTRK1CSF1RNTRK2PAK1PTPN11 | |
| SCHEMBL31435932 | 0.87 | PTPN11 (0.43) | NTRK1CSF1RNTRK2PAK1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | NTRK1 266/4885CSF1R 1635/4885NTRK2 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.